Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience

INTRODUCTION: OBJECTIVE: Immune thrombocytopenia (ITP) is an immune mediated disease characterized by transient or persistent decrease of the platelet count to less than 100 × 109/l. Although it is included in a benign disease group, bleeding complications may be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists which came into use in recent years, seem to be an effective option in the treatment of resistant patients. METHODS: In this study, retrospective data of 40 patients who were treated with Eltrombopag due to the diagnosis of refractory ITP in the Aegean region were examined and evaluated. RESULTS: In the study total rate of response was 87%, and in the cases with response the median period that number of platelets reached over 50. × 109/l was determined as 19.5 (5-60) days. DISCUSSION AND CONCLUSION: CONCLUSION: In one patient venous sinus thrombosis was observed and showed no other additional risk factor due to/ related to thrombosis. The other patient with complete response and irregular follow-up for 12 months was lost due to sudden death as the result of propable acute myocardial infarction.